Published in Kidney Int on June 01, 2004
Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest (2006) 3.41
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol (2009) 3.30
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab (2013) 2.63
Avosentan for overt diabetic nephropathy. J Am Soc Nephrol (2010) 2.32
Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol (2010) 2.22
Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol (2009) 2.12
Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol (2011) 2.07
Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol (2009) 2.04
Mechanisms of podocyte injury in diabetes: role of cytochrome P450 and NADPH oxidases. Diabetes (2009) 1.87
The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS Med (2008) 1.83
Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol (2009) 1.68
Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol (2011) 1.66
AMP-activated protein kinase (AMPK) negatively regulates Nox4-dependent activation of p53 and epithelial cell apoptosis in diabetes. J Biol Chem (2010) 1.60
Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol (2007) 1.59
The kidney in type 2 diabetes therapy. Rev Diabet Stud (2011) 1.50
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study. Clin Exp Nephrol (2006) 1.46
Proteinuria should be used as a surrogate in CKD. Nat Rev Nephrol (2012) 1.42
Evidence-based practice guideline for the treatment of CKD. Clin Exp Nephrol (2009) 1.29
The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol (2014) 1.27
Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care (2013) 1.26
Urine podocyte mRNAs, proteinuria, and progression in human glomerular diseases. J Am Soc Nephrol (2013) 1.20
Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol (2008) 1.19
Renal autoregulation in health and disease. Physiol Rev (2015) 1.18
initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial. Diabetes Care (2011) 1.18
Albuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con View. Clin J Am Soc Nephrol (2015) 1.18
Active vitamin D treatment for reduction of residual proteinuria: a systematic review. J Am Soc Nephrol (2013) 1.17
Low-grade albuminuria and cardiovascular risk : what is the evidence? Clin Res Cardiol (2007) 1.16
Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis. J Am Soc Nephrol (2014) 1.15
Angiotensin II infusion induces nephrin expression changes and podocyte apoptosis. Am J Nephrol (2008) 1.15
Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Diabetes Care (2010) 1.14
Slowing nephropathy progression: focus on proteinuria reduction. Clin J Am Soc Nephrol (2008) 1.11
Regulation of oxygen utilization by angiotensin II in chronic kidney disease. Kidney Int (2008) 1.08
Implementation of a CKD checklist for primary care providers. Clin J Am Soc Nephrol (2014) 1.07
Rate and determinants of association between advanced retinopathy and chronic kidney disease in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study. Diabetes Care (2012) 1.06
Involvement of endoplasmic reticulum stress in albuminuria induced inflammasome activation in renal proximal tubular cells. PLoS One (2013) 1.04
What do we know about chronic renal failure in young adults? II. Adult outcome of pediatric renal disease. Pediatr Nephrol (2009) 1.03
Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View. Clin J Am Soc Nephrol (2015) 1.03
Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake. Diabetes Care (2009) 0.99
Cardiovascular risk and management in chronic kidney disease. Nat Rev Nephrol (2009) 0.96
Renal protection in diabetes: lessons from ONTARGET. Cardiovasc Diabetol (2010) 0.95
Endothelial-podocyte crosstalk: the missing link between endothelial dysfunction and albuminuria in diabetes. Diabetes (2013) 0.93
Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis. Am J Kidney Dis (2014) 0.92
Amiloride as an Alternate Adjuvant Antiproteinuric Agent in Fabry Disease: The Potential Roles of Plasmin and uPAR. Case Rep Nephrol (2014) 0.91
Mild electrical stimulation and heat shock ameliorates progressive proteinuria and renal inflammation in mouse model of Alport syndrome. PLoS One (2012) 0.91
Mesenchymal stem cells modulate albumin-induced renal tubular inflammation and fibrosis. PLoS One (2014) 0.90
Skin autofluorescence is associated with the progression of chronic kidney disease: a prospective observational study. PLoS One (2013) 0.90
Management of Chronic Kidney Disease: The Relationship Between Serum Uric Acid and Development of Nephropathy. Adv Ther (2015) 0.90
Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat. Am J Physiol Renal Physiol (2009) 0.89
Simvastatin alleviates hyperpermeability of glomerular endothelial cells in early-stage diabetic nephropathy by inhibition of RhoA/ROCK1. PLoS One (2013) 0.87
Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients? Int J Nephrol Renovasc Dis (2010) 0.86
Lipotoxic disruption of NHE1 interaction with PI(4,5)P2 expedites proximal tubule apoptosis. J Clin Invest (2014) 0.86
Role of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension of chronic kidney disease and renoprotection. Study results. Hippokratia (2011) 0.86
Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. Vasc Health Risk Manag (2009) 0.85
Monitoring kidney function and albuminuria in patients with diabetes. Diabetes Care (2011) 0.85
Sustained delivery of IL-1Ra from PF127-gel reduces hyperglycemia in diabetic GK-rats. PLoS One (2013) 0.85
Association of chronic kidney disease (CKD) and failure to monitor renal function with adverse outcomes in people with diabetes: a primary care cohort study. BMC Nephrol (2013) 0.84
Proteinuria: an ignored marker of inflammation and cardiovascular disease in chronic hemodialysis. Int J Nephrol Renovasc Dis (2011) 0.84
Urinary biomarkers in obstructive nephropathy. Clin J Am Soc Nephrol (2012) 0.84
Association between remission of macroalbuminuria and preservation of renal function in patients with type 2 diabetes with overt proteinuria. Diabetes Care (2013) 0.84
Impact of vitamin D on chronic kidney diseases in non-dialysis patients: a meta-analysis of randomized controlled trials. PLoS One (2013) 0.84
Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. Clin J Am Soc Nephrol (2011) 0.84
Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis. J Am Soc Nephrol (2015) 0.84
Usefulness of RAS inhibition depends on baseline albuminuria. Nat Rev Nephrol (2010) 0.84
Application of direct renin inhibition to chronic kidney disease. Cardiovasc Drugs Ther (2010) 0.84
Present and future in the treatment of diabetic kidney disease. J Diabetes Res (2015) 0.84
Recent advances in managing and understanding diabetic nephropathy. F1000Res (2016) 0.83
Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset. Nephrol Dial Transplant (2010) 0.83
Genetic analysis of albuminuria in collaborative cross and multiple mouse intercross populations. Am J Physiol Renal Physiol (2012) 0.83
Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. PLoS One (2011) 0.83
The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers. Br J Clin Pharmacol (2015) 0.83
Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T). Vasc Health Risk Manag (2011) 0.82
Associations between structural and functional changes to the kidney in diabetic humans and mice. Life Sci (2013) 0.82
Paeoniflorin prevents diabetic nephropathy in rats. Comp Med (2009) 0.82
Prevalent Rate of Nonalbuminuric Renal Insufficiency and Its Association with Cardiovascular Disease Event in Korean Type 2 Diabetes. Endocrinol Metab (Seoul) (2016) 0.82
Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. EJC Suppl (2013) 0.81
Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy. Clin J Am Soc Nephrol (2013) 0.81
Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy. Clin J Am Soc Nephrol (2015) 0.81
Association of cholesterol levels with mortality and cardiovascular events among patients with CKD and different amounts of proteinuria. Clin J Am Soc Nephrol (2013) 0.81
Improving prognosis estimation in patients with heart failure and the cardiorenal syndrome. Int J Nephrol (2011) 0.81
Comparison of spironolactone and trichlormethiazide as add-on therapy to renin-angiotensin blockade for reduction of albuminuria in diabetic patients. J Diabetes Investig (2013) 0.81
Application of new acute kidney injury biomarkers in human randomized controlled trials. Kidney Int (2016) 0.80
Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy. Nat Rev Nephrol (2012) 0.80
Pharmacology: defining the optimal dose of a new drug: a crucial decision. Nat Rev Nephrol (2009) 0.80
Proteinuria, (99m) Tc-DTPA Scintigraphy, Creatinine-, Cystatin- and Combined-Based Equations in the Assessment of Chronic Kidney Disease. ISRN Nephrol (2014) 0.80
Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease. Chin Med J (Engl) (2016) 0.80
Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. Clin J Am Soc Nephrol (2016) 0.79
Effect of spironolactone combined with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers on chronic glomerular disease. Exp Ther Med (2013) 0.79
Cardiorenal connection in chronic kidney disease. Clin Exp Nephrol (2011) 0.79
Chapter 4: Blood pressure management in CKD ND patients with diabetes mellitus. Kidney Int Suppl (2011) (2012) 0.79
Renoprotective effects of a selective estrogen receptor modulator, raloxifene, in an animal model of diabetic nephropathy. Am J Nephrol (2007) 0.79
The next generation of therapeutics for chronic kidney disease. Nat Rev Drug Discov (2016) 0.79
Optimal proteinuria target for renoprotection in patients with IgA nephropathy. PLoS One (2014) 0.78
Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. J Am Soc Nephrol (2009) 0.78
Managing CKD: key therapeutic issues introduction. Clin J Am Soc Nephrol (2008) 0.78
Prevalence of microalbuminuria and risk factor analysis in type 2 diabetes patients in Albania: the need for accurate and early diagnosis of diabetic nephropathy. Hippokratia (2013) 0.78
Proteinuria and its relation to diverse biomarkers and body mass index in chronic hemodialysis. Int J Nephrol Renovasc Dis (2013) 0.78
A new mechanism for albuminuria-induced podocyte injury. J Am Soc Nephrol (2013) 0.78
Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials. BMJ Open Diabetes Res Care (2014) 0.78
Improving outcomes in diabetes and chronic kidney disease: the basis for Canadian guidelines. Can J Cardiol (2007) 0.78
Novel drugs and intervention strategies for the treatment of chronic kidney disease. Br J Clin Pharmacol (2013) 0.78
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med (2003) 20.06
Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med (2008) 18.27
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med (2009) 12.73
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet (2010) 7.69
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med (2013) 7.54
Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J (2004) 7.02
Preventing microalbuminuria in type 2 diabetes. N Engl J Med (2004) 6.41
Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest (2003) 6.30
The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int (2011) 6.21
Atypical hemolytic-uremic syndrome. N Engl J Med (2009) 5.66
Cachexia: a new definition. Clin Nutr (2008) 5.49
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med (2003) 5.47
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int (2011) 5.25
Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood (2006) 4.51
Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med (2008) 4.25
Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes (2008) 4.13
Nephropathy in diabetes. Diabetes Care (2004) 4.08
Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol (2006) 4.01
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int (2011) 3.96
Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int (2003) 3.95
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol (2010) 3.82
Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol (2012) 3.79
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation (2004) 3.78
Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet (2005) 3.52
How does proteinuria cause progressive renal damage? J Am Soc Nephrol (2006) 3.46
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int (2013) 3.42
Mechanisms of diabetic complications. Physiol Rev (2013) 3.41
Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol (2004) 3.41
Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med (2012) 3.31
Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int (2008) 3.27
Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med (2009) 3.24
Hemolytic uremic syndrome. J Am Soc Nephrol (2005) 3.19
Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med (2011) 3.17
Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol (2011) 3.13
Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care (2003) 3.12
Delayed graft function in kidney transplantation. Lancet (2004) 3.06
Clinical review: The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab (2008) 3.00
Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest (2004) 2.98
Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest (2003) 2.96
Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int (2002) 2.92
Decision time for pancreatic islet-cell transplantation. Lancet (2008) 2.91
Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis (2003) 2.86
Familial haemolytic uraemic syndrome and an MCP mutation. Lancet (2003) 2.79
Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet (2003) 2.71
A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res (2003) 2.69
Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis (2003) 2.68
Renal progenitors: an evolutionary conserved strategy for kidney regeneration. Nat Rev Nephrol (2013) 2.66
Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J (2005) 2.66
MYO1E mutations and childhood familial focal segmental glomerulosclerosis. N Engl J Med (2011) 2.65
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med (2014) 2.64
Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ (2004) 2.62
Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology (2006) 2.62
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol (2007) 2.61
Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol (2011) 2.60
Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. Kidney Int (2011) 2.52
Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes (2007) 2.51
Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. Stem Cells (2008) 2.51
Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol (2006) 2.51
Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest (2009) 2.49
Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol (2008) 2.48
Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med (2003) 2.45
The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int (2003) 2.43
Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis (2004) 2.43
Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol (2010) 2.42
Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant (2002) 2.41
Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes (2008) 2.41
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol (2006) 2.37